Vimarsana
Biggest News Aggregation in the World

Page 20 - Equity Strategy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Equity Strategy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Equity Strategy Today - Breaking & Trending Today

AU Bank enters Jefferies India portfolio, CAMS exits; Here's why Chris Wood is taking contra bets? - Vimarsana News

AU Bank enters Jefferies India portfolio, CAMS exits; Here's why Chris Wood is taking contra bets?

Chris Wood, the Global Head of Equity Strategy of Jefferies, has added AU Small Finance Bank in his India portfolio, with a 3 per cent weightage.

Madison Covered Call & Equity Strategy Fund Announces Quarterly Dividend of $0.18 (NYSE:MCN) - Vimarsana News

Madison Covered Call & Equity Strategy Fund Announces Quarterly Dividend of $0.18 (NYSE:MCN)

Madison Covered Call & Equity Strategy Fund (NYSE:MCN – Get Rating) declared a quarterly dividend on Friday, June 2nd, Wall Street Journal reports. Stockholders of record on Friday, June 16th will be given a dividend of 0.18 per share by the investment management company on Friday, June 30th. This represents a $0.72 annualized dividend and […]

'Only a Matter of Time': Chris Wood of Jefferies Sees Sensex Reaching 100,000 Points - Vimarsana News

'Only a Matter of Time': Chris Wood of Jefferies Sees Sensex Reaching 100,000 Points

Last year in February 2022, Chris Wood in a note had stated that India's benchmark BSE Sensex to hit 100,000 on a five-year view i.e. by late 2026.

Source: news18.com
Chris Wood adds Axis Bank, Thermax to portfolio, increases L&T's weight - Vimarsana News

Chris Wood adds Axis Bank, Thermax to portfolio, increases L&T's weight

Wood's move comes on the heels of Axis Bank's merger with Citibank's India consumer business

Mankind Pharma shares extend gain after solid listing; should you stay put or book profits? - Vimarsana News

Mankind Pharma shares extend gain after solid listing; should you stay put or book profits?

The bullish momentum in Mankind Pharma continued even after listing as the stock advanced another 9 per cent to Rs 1,414, extending the overall gains to about 31 per cent.